Skip to main content

Abstract

Efficient Data Analysis (EDA) was designed specifically to address quality control (QC) decisions with respect to the CI-measured APSD from an OIP. The general goal of QC testing is to confirm that the batch in question is of suitable quality. In the case of EDA, this testing is intended to confirm that the OIP in question generates an aerosol with expected particle size characteristics to deliver drug to the human respiratory tract. Note that this process necessarily takes the form of sampling a relatively small number of units, measuring properties of the aerosols generated by these samples, and making a decision concerning the quality of the sampled batch. This practice leads to three primary considerations:

  1. 1.

    The properties measured should be relevant to detecting significant abnormalities from the expected APSD.

  2. 2.

    The measurements should possess sufficient precision and accuracy over the range of interest.

  3. 3.

    The decision process based on the measurements should reliably make correct inference about the quality of the batch by appropriately minimizing and balancing the risk of decision errors, i.e., judging a batch suitable when it is not suitable and conversely judging a batch unsuitable when it is suitable.

This chapter will briefly introduce the latter two considerations, but will primarily focus on the first. A detailed discussion of the evaluation of measurements and the decision-making process is the topic of Chap. 8.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Newman SP, Chan H-K (2008) In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med 21(1):1–8

    Google Scholar 

  2. Heyder J, Svartengren MU (2002) Basic principles of particle behavior in the human respiratory tract. In: Bisgaard H, O’Callaghan C, Smaldone GC (eds) Drug delivery to the lung. Marcel Dekker, New York

    Google Scholar 

  3. Dolovich M (2002) Airway delivery devices and airways/lung deposition. In: Schleimer R, O’Byrne PM, Szefler S, Brattsand R (eds) Inhaled steroids in asthma. Marcel Dekker, New York, NY, pp 169–212

    Google Scholar 

  4. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ (2003) Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol 95:2106–2112

    PubMed  Google Scholar 

  5. Usmani OS, Biddiscombe MF, Barnes PJ (2005) Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med 172(12):1497–1504

    Article  PubMed  Google Scholar 

  6. Zanen P, Go LT, Lammers JWJ (1994) The optimal particle size for beta-adrenergic aerosols in mild asthmatics. Int J Pharm 107:211–217

    Article  CAS  Google Scholar 

  7. Zanen P, Go LT, Lammers JWJ (1995) The optimal particle size for parasympathicolytic aerosols in mild asthmatics. Int J Pharm 114:111–115

    Article  CAS  Google Scholar 

  8. Zanen P, Go LT, Lammers JWJ (1996) Optimal particle size for beta-agonist and anticholinergic aerosols in patients with severe airflow limitation. Thorax 51:977–980

    Article  PubMed  CAS  Google Scholar 

  9. Newman SP (1998) How well do in vitro particle size measurements predict drug delivery in vivo? J Aerosol Med 11(S1):S97–S104

    PubMed  Google Scholar 

  10. Newman SP, Wilding IR, Hirst PH (2000) Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 208:49–60

    Article  PubMed  CAS  Google Scholar 

  11. Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, Lyapustina S (2009) Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs). AAPS PharmSciTech 10(4):1276–1285

    Article  PubMed  CAS  Google Scholar 

  12. Wheeler DJ (2006) EMP (evaluating the measurement process) III: using imperfect data. SPC, Knoxville, TN

    Google Scholar 

  13. AIAG (Automotive Industry Action Group) (2010) Measurement system analysis, reference manual, 4th edn. AIAG, Southfield, MI, USA, ISBN#: 978-1-60-534211-5

    Google Scholar 

  14. Bower KM, Touchton ME (2001) Evaluating the usefulness of data by gage repeatability and reproducibility. Asia Pacific Process Engineer. http://www.minitab.com/en-US/training/articles/default.aspx. Accessed 22 July 2012

  15. Tougas TP (2006) Considerations of the role of end product testing in assuring the quality of pharmaceutical products. Process Anal Technol 3:13–17

    Google Scholar 

  16. Summers DCS (1997) Quality. Prentice Hall, Upper Saddle River, NJ

    Google Scholar 

  17. Dunbar C, Mitchell JP (2005) Analysis of cascade impactor mass distributions. J Aerosol Med 18(4):439–451

    Article  PubMed  CAS  Google Scholar 

  18. Marple VA, Roberts DL, Romay FJ, Miller NC, Truman KG, Van Oort M, Olsson B, Holroyd MJ, Mitchell JP, Hochrainer D (2003) Next generation pharmaceutical impactor. Part 1: Design. J Aerosol Med 16:283–299

    Article  PubMed  Google Scholar 

  19. Mitchell JP, Nagel MW (2003) Cascade impactors for the size characterization of aerosols from medical inhalers; their uses and limitations. J Aerosol Med 16:341–376

    Article  PubMed  CAS  Google Scholar 

  20. O’Shaughnessy PT, Raabe OG (2003) A comparison of cascade impactor data reduction methods. Aerosol Sci Technol 37(2):187–200

    Article  Google Scholar 

  21. US Food and Drug Administration (FDA) (1998) CDER. Draft guidance for industry metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products chemistry, manufacturing, and controls documentation, Rockville, MD, USA. http://www.fda.gov/cder/guidance/2180dft.pdf. Accessed 15 July 2012

  22. European Medicines Agency (EMA) (2006) Guideline on the pharmaceutical quality of inhalation and nasal products. London, UK, EMEA/CHMP/QWP/49313/2005 Final. http://www.ema.europa.eu/pdfs/human/qwp/4931305en.pdf. Accessed 20 Jan 2012

  23. Health Canada (2006) Guidance for industry: pharmaceutical quality of inhalation and nasal products. File Number file number: 06-106624-547. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/inhalationnas-eng.pdf. Accessed 20 Jan 2012

  24. Hinds WC (1999) Aerosol technology: properties, behavior, and measurement of airborne particles, 2nd edn. John Wiley & Sons, New York

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Terrence P. Tougas .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Tougas, T.P., Mitchell, J.P. (2013). Theoretical Basis for the EDA Concept. In: Tougas, T., Mitchell, J., Lyapustina, S. (eds) Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-6296-5_7

Download citation

Publish with us

Policies and ethics